QRL-101 clinical trials
Also written QRL-101.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses QRL-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QRL-101
- 5
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
QurAlis Corporation (6)
Studies
Open first, then newest update. How each study uses QRL-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy ParticipantsCompletedPhase 1QurAlis CorporationNCT07421778Written as QRL-101
- A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALSCompletedPhase 1QurAlis CorporationNCT06714396Written as QRL-101
- A Study Evaluating the Pharmacokinetics of Three QRL-101 Formulations in Healthy ParticipantsCompletedPhase 1QurAlis CorporationNCT06877624Written as QRL-101
- A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy ParticipantsCompletedPhase 1QurAlis CorporationNCT06681441Written as QRL-101 Dose A
- A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy ParticipantsCompletedPhase 1QurAlis CorporationNCT06532396Written as QRL-101
- A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy ParticipantsCompletedPhase 1QurAlis CorporationNCT05667779Written as QRL-101